Miller EA, et al. - Researchers assessed if lower prostate cancer (PCa) rates reported in men with diabetes are attributable to a lower risk of the disease or a bias in detection from prostate-specific antigen (PSA) testing. For this purpose, they used data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial. They found lower rates of PCa among men with diabetes; this finding was limited to low- and intermediate-grade tumors. Following first positive screening test, the likelihood of being biopsied in men with diabetes was less. Significantly more advanced tumors with higher PSA levels were detected in men diagnosed with low/intermediate-grade tumors. Overall, findings highlight a likely contribution of detection bias to the lower rates of low- and intermediate-grade prostate cancers found in diabetics.